[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334014-105":59,"doc-detail-334014-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ultrasound-radiomics-for-the-prediction-of-breast-cancers-with-her2-zero-low-and-positive-status-a-dual-center-study","Ultrasound Radiomics for the Prediction of Breast Cancers with HER2-Zero - Low and - Positive Status - A Dual-Center Study","","The study evaluates whether gray-scale ultrasound (US) radiomic features can distinguish HER2 expression patterns in breast cancer, specifically HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing. Using retrospective data from two centers (Feb 2021 to Jul 2023), tumor segmentation and radiomic extraction were combined with decision-tree feature importance, LASSO feature selection, and receiver operating characteristic performance. Multivariate logistic regression identified independent predictors. Results were tested on an external validation set, supporting radiomic signatures for clinically relevant HER2 stratification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ultrasound-radiomics-for-the-prediction-of-breast-cancers-with-her2-zero-low-and-positive-status-a-dual-center-study/334014/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ultrasound-radiomics-for-the-prediction-of-breast-cancers-with-her2-zero-low-and-positive-status-a-dual-center-study/334014.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of this study?","Question",{"text":112,"@type":113},"To assess whether gray-scale ultrasound-based radiomic features can distinguish different HER2 expression levels in breast cancer, including HER2-zero, HER2-low, and HER2-positive states.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were radiomic features selected and evaluated?",{"text":117,"@type":113},"Tumor segmentation and radiomic feature extraction were performed on grayscale US images. Decision tree analysis assessed feature importance, LASSO was used for feature selection, and ROC AUC quantified performance. Multivariate logistic regression identified independent predictors.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main performance results in the external validation set?",{"text":121,"@type":113},"For distinguishing HER2-low/positive versus HER2-zero, radiomic features achieved an AUC of 0.76. For differentiating HER2-low (1+) from HER2-zero the AUC was 0.74, and for HER2-low (2+) from HER2-zero it was 0.77.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334014,1790192555,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Ultrasound Radiomics for the Prediction of Breast Cancers with HER2-Zero, -Low, and-Positive Status: A Dual-Center Study  \nYunqing Yin, MD3,†, Sijie Mo, MD3,†, Guoqiu Li, MD 1,†, Huaiyu Wu, PhD 1, Jintao Hu, MD2, Jing Zheng, MD 1, Qinghua Liu, MD4, Mengyun Wang, MD 1, Jinfeng Xu, PhD 1,  \nZhibin Huang, MD 1 , Hongtian Tian, MD 1, and Fajin Dong, PhD 1  \nTechnology in Cancer Research & Treatment  \nVolume 23: 1-11  \n© The Author(s) 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/15330338241292668](DOI: 10.1177/15330338241292668)[ ](DOI: 10.1177/15330338241292668)[journals.sagepub.com/home/tct](journals.sagepub.com/home/tct)  \nAbstract  \nPurpose: To assess whether gray-scale ultrasound (US) based radiomic features can help distinguish HER2 expressions (ie, HER2-overexpressing, HER2-low-expressing, and HER2-zero-expressing) in breast cancer. Materials and Methods: This retrospective study encompassed female breast cancer patients who underwent US examinations at two distinct centers from February 2021 to July 2023. Tumor segmentation and radiomic feature extraction were performed on grayscale US images. Decision Tree analysis was employed to simultaneously evaluate feature importance, and the Least Absolute Shrinkage and Selection Operator technique was utilized for feature selection to construct the radiomic signature. The Area Under the Curve (AUC) of the Receiver Operating Characteristic curve was employed to assess the performance of the radiomic features. Multivariate logistic regression was used to identify independent predictors for distinguishing HER2 expression in the dataset. Results: The training set comprised 292 patients from Center 1 (median, 51 years; interquartile range [IQR]: 45-61), while the external validation set included 131 patients from Center 2 (median, 51 years; IQR: 45-62). In the external validation dataset, the radiomic features achieved AUC of 0.76 for distinguishing between HER2-low and positive tumors versus HER2-zero tumors. The AUC for differentiating HER2-low (1 +) from HER2-zero tumors was 0.74, and for distinguishing HER2-low (2+) from HER2-zero tumors, the AUC was 0.77. In the multivariate analysis assessing HER2-low and HER2-positive versus HER2-zero tumors, internal echoes (P = .029) and margins (P\u003C.001) emerged as independent predictive factors. Conclusion: The radiomic signature and tumor descriptors from gray-scale US may predict distinct HER2 expressions of breast cancers with therapeutic implications.  \nKeywords  \nbreast cancer, HER2, radiomic, ultrasound  \n1 Department of Ultrasound, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), Shenzhen, Guangdong, China  \n2 Department of Pathology, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Afﬁliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China  \n3 The Second Clinical Medical College, Jinan University, Shenzhen, Guangdong, China  \n4 Department of Ultrasound, Rizhao People’s Hospital, Rizhao, Shandong, China  \n† These authors contributed equally to this work.  \nCorresponding Authors:  \nZhibin Huang, Department of Ultrasound, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), Shenzhen, Guangdong, China. Email: [zbhuangsz@gmail.com](zbhuangsz@gmail.com);  \nHongtian Tian, Department of Ultrasound, The Second Clinical Medical College, Jinan University (Shenzhen People’s Hospital), Shenzhen, Guangdong, China. Email: [tianhongtian@szhospital.com](tianhongtian@szhospital.com);  \nFajin Dong, Department of Ultrasound, Shenzhen People’ s Hospital (The Second Clinical Medical College, Jinan University; The First Afﬁliated Hospital, Southern University of Science and Technology), Guangdong 518020, China.  \nEmail: [dongfajin@szhospital.com](dongfajin@szhospital.com).  \nCreative Commons Non Commercial CC ","cbCaiqPje2htous7","https://ap.wps.com/l/cbCaiqPje2htous7","pdf",958035,11,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusion\n# Keywords\n# Abbreviations\n# Key Points","[{\"question\":\"What is the purpose of this study?\",\"answer\":\"To assess whether gray-scale ultrasound-based radiomic features can distinguish different HER2 expression levels in breast cancer, including HER2-zero, HER2-low, and HER2-positive states.\"},{\"question\":\"How were radiomic features selected and evaluated?\",\"answer\":\"Tumor segmentation and radiomic feature extraction were performed on grayscale US images. Decision tree analysis assessed feature importance, LASSO was used for feature selection, and ROC AUC quantified performance. Multivariate logistic regression identified independent predictors.\"},{\"question\":\"What were the main performance results in the external validation set?\",\"answer\":\"For distinguishing HER2-low/positive versus HER2-zero, radiomic features achieved an AUC of 0.76. For differentiating HER2-low (1+) from HER2-zero the AUC was 0.74, and for HER2-low (2+) from HER2-zero it was 0.77.\"}]","Ultrasound Radiomics for the Prediction of Breast Cancers with HER2-Zero - Low and - Positive Status - A Dual-Center Study | PDF",1790004993,28]